



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2018/031263

(22) International Filing Date:

04 May 2018 (04.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/501,981 05 May 2017 (05.05.2017) US

(71) Applicant: VACCINEX, INC. [US/US]; 1895 Mount Hope Avenue, Rochester, New York 14620 (US).

(72) Inventors: SMITH, Ernest S.; 67 Longton Place, W. Henrietta, New York 14586 (US). CORNELISON, Angelica; 14 Rainbrooke Drive, Pittsford, New York 14534 (US). SCRIVENS, Maria G.M.; 71 Courtly Circle, Rochester, New York 14615 (US). PARIS, Mark; 24 Bosworth Field, Mendon, New York 14506 (US). ZAUDERER, Maurice; 44 Woodland Road, Pittsford, New York 14534 (US).


(74) Agent: HAANES, Elizabeth J. et al.; Fisherbroyles LLP, 945 East Paces Ferry Road NE, Suite 2000, Atlanta, Georgia 30328 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUMAN ANTI-SEMAPHORIN 4D ANTIBODY

FIGURE 1



(57) Abstract: Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*